Assessment of Asymptomatic Microscopic Hematuria in Adults VICTORIA J

Total Page:16

File Type:pdf, Size:1020Kb

Assessment of Asymptomatic Microscopic Hematuria in Adults VICTORIA J Assessment of Asymptomatic Microscopic Hematuria in Adults VICTORIA J. SHARP, MD, MBA; KERRI T. BARNES, MD, MPH; and BRADLEY A. ERICKSON, MD, MS University of Iowa Hospitals and Clinics, Iowa City, Iowa Although routine screening for bladder cancer is not recommended, microscopic hematuria is often incidentally dis- covered by primary care physicians. The American Urological Association has published an updated guideline for the management of asymptomatic microscopic hematuria, which is defined as the presence of three or more red blood cells per high-power field visible in a properly collected urine specimen without evidence of infection. The most com- mon causes of microscopic hematuria are urinary tract infection, benign prostatic hyperplasia, and urinary calculi. However, up to 5% of patients with asymptomatic microscopic hematuria are found to have a urinary tract malig- nancy. The risk of urologic malignancy is increased in men, persons older than 35 years, and persons with a history of smoking. Microscopic hematuria in the setting of urinary tract infection should resolve after appropriate antibiotic treatment; persistence of hematuria warrants a diagnostic workup. Dysmorphic red blood cells, cellular casts, protein- uria, elevated creatinine levels, or hypertension in the presence of microscopic hematuria should prompt concurrent nephrologic and urologic referral. The upper urinary tract is best evaluated with multiphasic computed tomography urography, which identifies hydronephrosis, urinary calculi, and renal and ureteral lesions. The lower urinary tract is best evaluated with cystoscopy for urethral stricture disease, benign prostatic hyperplasia, and bladder masses. Voided urine cytology is no longer recommended as part of the routine evaluation of asymptomatic microscopic hematuria, unless there are risk factors for malignancy. (Am Fam Physician. 2013;88(11):747-754. Copyright © 2013 American Academy of Family Physicians.) Author disclosure: No rel- n its 2011 recommendation statement, hematuria and in up to 30% to 40% of evant financial affiliations. the U.S. Preventive Services Task Force patients with gross hematuria.8 Studies CME This clinical content did not find sufficient evidence for or have revealed that recommended diagnostic conforms to AAFP criteria against screening for bladder cancer in guidelines are rarely followed, resulting in for continuing medical I asymptomatic adults.1 Despite this, micro- inappropriate and costly referrals, and fail- education (CME). See CME Quiz Questions on page scopic hematuria is often found inciden- ure to detect many treatable causes of hema- 732. tally during routine health screenings, with turia.7-9 Although the reasons for this lack of ▲ 2-6 Patient information: a prevalence of about 2% to 31%. Because adherence to guideline recommendations A handout on this topic primary care physicians commonly are the are unclear, they are likely secondary to a is available at http:// first to recognize asymptomatic microscopic combination of factors, including confusion familydoctor.org/family hematuria, an evidence-based approach to about suggested workup, the rarity of find- doctor/en/diseases- conditions/microscopic- the evaluation of hematuria is necessary. ing clinically significant etiologies, patient hematuria.html. In 2012, the American Urological Associa- compliance with follow-up, and costs.7,10,11 tion (AUA) published an updated guideline An algorithmic approach to the diagnosis on the diagnosis, evaluation, and follow-up and management of asymptomatic micro- of asymptomatic microscopic hematuria in scopic hematuria is provided in Figure 1.6,12-14 adults.6 Based on the guideline, this article describes the current approaches to diagno- Etiology sis, follow-up, and referral for patients with Hundreds of diseases have been shown to asymptomatic microscopic hematuria. cause hematuria. In the small percentage of In many patients with microscopic hema- patients for whom an etiology is identified, turia, a specific cause or pathology is not causes may include urinary tract infection, found.7 Nevertheless, formal evaluation is benign prostatic hyperplasia, medical renal critical, because malignancies are detected disease, urinary calculi, urethral stricture in up to 5% of patients with microscopic disease, and urologic malignancy.6-8,15 Table 1 DownloadedDecember 1,from 2013 the ◆American Volume Family 88, Number Physician 11website at www.aafp.org/afp.www.aafp.org/afp Copyright © 2013 American Academy of FamilyAmerican Physicians. Family For the Physicianprivate, non -747 commercial use of one individual user of the website. All other rights reserved. Contact [email protected] for copyright questions and/or permission requests. Microscopic Hematuria Diagnosis and Management of Incidentally Discovered Microscopic Hematuria Dipstick testing positive for blood A Assess for: Risk factors for malignancy (Table 2) Contraindications to radiation Microscopic urinalysis Contrast media allergies Renal insufficiency Less than three red blood cells per high-power field Low risk of malignancy High risk of malignancy or and/or Repeat urinalysis three Renal insufficiency Good renal function times at six-week intervals Radiation sensitivity No contrast media allergy Contrast media allergy No contraindications to radiation Negative Positive Less optimal imaging option (e.g., magnetic Computed tomography No additional Three or more red blood resonance urography, renal ultrasonography, urography and workup cells per high-power field noncontrast computed tomography, urologic referral magnetic resonance imaging, retrograde pyelography) and urologic referral Assess for urinary tract infection and other benign causes (e.g., vigorous exercise, menstruation, recent urologic procedure) Repeat urinalysis six weeks after treatment or discontinuation of contributing factor Cystoscopy Negative Positive Negative Positive No additional workup Renal function testing to assess Annual urinalysis for two years Treat for medical renal disease (e.g., dysmorphic red blood cells, cellular casts, proteinuria) Negative Positive Release from care Annual repeat urinalysis positive; repeat anatomic evaluation Negative Positive within three to five years Go to A Concurrent nephrologic referral Figure 1. Algorithm for the diagnosis and management of incidentally discovered microscopic hematuria. Adapted with permission from Davis R, Jones JS, Barocas DA, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. American Urological Association Education and Research, Inc., 2012:1-30, with additional information from references 12 through 14. lists the most common etiologies after ini- minute for 10 minutes (the number of revo- tial evaluation of microscopic hematuria.2,7-9 lutions and minutes may vary, depending The risk of urologic malignancy increases on the centrifuge). The supernatant should significantly in men, persons older than be discarded and the sediment suspended 35 years, and persons with a history of smok- in 0.3 mL of supernatant and/or saline, and ing.1,6 Table 2 lists other factors that have placed on a microscopic slide. At least 10 to been shown to increase the risk of urologic 20 microscopic fields should be examined malignancy in patients with asymptomatic under 400× magnification.16 According to the microscopic hematuria.6 AUA, the presence of three or more red blood cells on a single, properly collected, noncon- Clinical Relevance taminated urinalysis without evidence of CONFIRMATION OF HEMATURIA infection is considered clinically significant The most important test in the evaluation microscopic hematuria.6 If the specimen of hematuria is a microscopic examination shows large amounts of squamous epithelial of the urine.6 Approximately 10 mL of mid- cells (more than five per high-power field) or stream urine should be collected and imme- if the patient is unable to provide an uncon- diately centrifuged at 2,000 revolutions per taminated specimen secondary to anatomic 748 American Family Physician www.aafp.org/afp Volume 88, Number 11 ◆ December 1, 2013 Microscopic Hematuria Table 1. Common Etiologies of Microscopic Hematuria Diagnosis Frequency (%) the presence of hemoglobinuria, myoglo- Unknown 43 to 68 binuria, semen, highly alkaline urine (pH Urinary tract infection 4 to 22 greater than 9), and concentrated urine.12,19 Benign prostatic hyperplasia 10 to 13 Ascorbic acid (vitamin C) has been shown Urinary calculi 4 to 5 to cause false-negative results on dipstick Bladder cancer 2 to 4 testing because of its reducing properties; Renal cystic disease 2 to 3 therefore, patients taking vitamin C supple- Renal disease 2 to 3 ments and undergoing urinary evaluation Kidney cancer < 1 may benefit from up-front microscopic Prostate cancer < 1 examination.20 Urethral stricture disease < 1 POSITIVE DIPSTICK TEST Information from references 2, and 7 through 9. AND NEGATIVE MICROSCOPIC RESULTS Patients who screen positive for hematuria with a urine dipstick test but have a negative Table 2. Common Risk Factors for follow-up microscopic examination should Urinary Tract Malignancy in Patients undergo three additional microscopic tests with Microscopic Hematuria to rule out hematuria. If one of these repeat test results is positive on microscopic analy- Age older than 35 years sis, the patient is considered to have micro- Analgesic abuse scopic hematuria. If all three specimens are Exposure to chemicals or dyes (benzenes or negative on microscopy, the patient
Recommended publications
  • Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis
    cancer.org | 1.800.227.2345 Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Finding cancer early, when it's small and hasn't spread, often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that's not always the case. ● Can Bladder Cancer Be Found Early? ● Bladder Cancer Signs and Symptoms ● Tests for Bladder Cancer Stages and Outlook (Prognosis) After a cancer diagnosis, staging provides important information about the extent (amount) of cancer in the body and the likely response to treatment. ● Bladder Cancer Stages ● Survival Rates for Bladder Cancer Questions to Ask About Bladder Cancer Here are some questions you can ask your cancer care team to help you better understand your cancer diagnosis and treatment options. ● Questions To Ask About Bladder Cancer 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Bladder Cancer Be Found Early? Bladder cancer can sometimes be found early -- when it's small and hasn't spread beyond the bladder. Finding it early improves your chances that treatment will work. Screening for bladder cancer Screening is the use of tests or exams to look for a disease in people who have no symptoms. At this time, no major professional organizations recommend routine screening of the general public for bladder cancer. This is because no screening test has been shown to lower the risk of dying from bladder cancer in people who are at average risk. Some providers may recommend bladder cancer tests for people at very high risk, such as: ● People who had bladder cancer before ● People who had certain birth defects of the bladder ● People exposed to certain chemicals at work Tests that might be used to look for bladder cancer Tests for bladder cancer look for different substances and/or cancer cells in the urine.
    [Show full text]
  • Chapter 99 – Urological Disorders Episode Overview Urinary Tract Infections in Adults 1
    Crack Cast Show Notes – Urological Disorders – August 2017 www.crackcast.org Chapter 99 – Urological Disorders Episode Overview Urinary Tract Infections in Adults 1. Differentiate between the three major causes of dysuria in women? (ddx of dysuria) 2. List 3 common UTI pathogens, and list 3 additional pathogens in complicated UTIs 3. Define uncomplicated UTI and antibiotic options 4. Define complicated UTI and antibiotic options 5. List two antibiotic options for uncomplicated and complicated pyelonephritis. 6. How is pyelonephritis managed in pregnancy? What are safe antibiotic options for bacteriuria in pregnancy? Prostatitis 1. Describe the diagnosis and management of prostatitis Renal Calculi 1. Name the areas of narrowing in the ureter 2. Name 6 risk factors for urolithiasis 3. List 8 alternative diagnoses (other than renal colic) for pain associated with urolithiasis 4. What are indications for hospitalization of patients with urolithiasis Bladder (Vesical) Calculi 1. Describe this condition and its management Acute Scrotal Pain 1. List causes of acute scrotal swelling by age groups (infant, child, adolescent, adult) 2. Describe the physiology, diagnosis and management of testicular torsion 3. Describe the treatment for sexually vs. non-sexually acquired epididymitis Acute Urinary Retention 1. Describe the physiology of urination 2. List 10 causes of acute urinary retention in adults 3. List 6 causes of urinary retention in women Hematuria 1. List causes of red-coloured urine without hematuria 2. List risk factors for urinary tract malignancy Wisecracks: 1. When is a urine culture indicated (box 89.1) 2. What is a CAUTI and how is it managed? 3. What are two medication classes of drugs for prostatic enlargement? 4.
    [Show full text]
  • Clinical Usefulness of Urine Cytology in the Detection of Bladder Tumors in Patients with Neurogenic Lower Urinary Tract Dysfunction
    Journal name: Research and Reports in Urology Article Designation: ORIGINAL RESEARCH Year: 2017 Volume: 9 Research and Reports in Urology Dovepress Running head verso: Pannek et al Running head recto: Cytology for bladder tumor detection in neurogenic bladder open access to scientific and medical research DOI: http://dx.doi.org/10.2147/RRU.S148429 Open Access Full Text Article ORIGINAL RESEARCH Clinical usefulness of urine cytology in the detection of bladder tumors in patients with neurogenic lower urinary tract dysfunction Jürgen Pannek Introduction: Screening for bladder cancer in patients with neurogenic lower urinary tract Franziska Rademacher dysfunction is a challenge. Cystoscopy alone is not sufficient to detect bladder tumors in this Jens Wöllner patient group. We investigated the usefulness of combined cystoscopy and urine cytology. Materials and methods: By a systematic chart review, we identified all patients with neuro- Neuro-Urology, Swiss Paraplegic Center, Nottwil, Switzerland genic lower urinary tract dysfunction who underwent combined cystoscopy and urine cytology testing. In patients with suspicious findings either in cytology or cystoscopy, transurethral resection was performed. Results: Seventy-nine patients (age 54.8±14.3 years, 38 female, 41 male) were identified; 44 of these used indwelling catheters. Cystoscopy was suspicious in 25 patients and cytology was suspicious in 17 patients. Histologically, no tumor was found in 15 patients and bladder cancer was found in 6 patients. Sensitivity for both cytology and cystoscopy was 83.3%; specificity was 43.7% for cytology and 31.2% for cystoscopy. One bladder tumor was missed by cytology and three tumors were missed by cystoscopy. If a biopsy was taken only if both findings were suspicious, four patients would have been spared the procedure, and one tumor would not have been diagnosed.
    [Show full text]
  • Paroxysmal Nocturnal Hemoglobinuria
    Paroxysmal nocturnal hemoglobinuria Description Paroxysmal nocturnal hemoglobinuria is an acquired disorder that leads to the premature death and impaired production of blood cells. The disorder affects red blood cells (erythrocytes), which carry oxygen; white blood cells (leukocytes), which protect the body from infection; and platelets (thrombocytes), which are involved in blood clotting. Paroxysmal nocturnal hemoglobinuria affects both sexes equally, and can occur at any age, although it is most often diagnosed in young adulthood. People with paroxysmal nocturnal hemoglobinuria have sudden, recurring episodes of symptoms (paroxysmal symptoms), which may be triggered by stresses on the body, such as infections or physical exertion. During these episodes, red blood cells are prematurely destroyed (hemolysis). Affected individuals may pass dark-colored urine due to the presence of hemoglobin, the oxygen-carrying protein in blood. The abnormal presence of hemoglobin in the urine is called hemoglobinuria. In many, but not all cases, hemoglobinuria is most noticeable in the morning, upon passing urine that has accumulated in the bladder during the night (nocturnal). The premature destruction of red blood cells results in a deficiency of these cells in the blood (hemolytic anemia), which can cause signs and symptoms such as fatigue, weakness, abnormally pale skin (pallor), shortness of breath, and an increased heart rate. People with paroxysmal nocturnal hemoglobinuria may also be prone to infections due to a deficiency of white blood cells. Abnormal platelets associated with paroxysmal nocturnal hemoglobinuria can cause problems in the blood clotting process. As a result, people with this disorder may experience abnormal blood clotting (thrombosis), especially in large abdominal veins; or, less often, episodes of severe bleeding (hemorrhage).
    [Show full text]
  • The Effect of Flood Diuresis on Hemo-Globinuria
    THE EFFECT OF FLOOD DIURESIS ON HEMO- GLOBINURIA. BY HERBERT HAESSLERj M.D. (From the Laboratories of The Rockefeller Inatitute for Medical Research.) (Received for publication, November 9, 1921.) The fact is well recognized that a considerable quantity of hemo- globin must be free in the plasma if any is to pass the renal barrier and appear in the urine. The pigment is, like dextrose, a "threshold substance." It readily penetrates into the renal tubules but is absorbed again more or less completely during its course through them. t This being true, diuresis should diminish the chances of absorption by hastening the flow of fluid, and tend to lead to the appearance of the pigment in the urine. Evidence will here be presented that such is the case. Hemoglobinuria, like glycosuria, is much favored by flood diuresis. Method. A concentrated solution of hemoglobin was abruptly thrown into the circulation of rabbits and dogs, followed in some instances by a slower injection of salt solution. The amount of pigment introduced was slightly less than that required to produce hemoglobinuria in the absence of diuresis. The urine was collected at intervals by catheter. All of the animals were males. Individuals were selected with normal kidneys, as indicated by ~e general character of the urine and proven by the autopsy findings. Great care was necessary to prevent hemorrhage during the catheterization of the rabbits, and despite it a few red cells were frequently encountered after- wards in the urine. For this reason the experiments were repeated on dogs, in which the complication can be avoided.
    [Show full text]
  • Prevalence of Microhematuria in Renal Colic and Urolithiasis: a Systematic Review and Meta-Analysis
    Minotti et al. BMC Urology (2020) 20:119 https://doi.org/10.1186/s12894-020-00690-7 RESEARCH ARTICLE Open Access Prevalence of microhematuria in renal colic and urolithiasis: a systematic review and meta-analysis Bruno Minotti1* , Giorgio Treglia2, Mariarosa Pascale3, Samuele Ceruti4, Laura Cantini5, Luciano Anselmi5 and Andrea Saporito5 Abstract Background: This systematic review and meta-analysis aims to investigate the prevalence of microhematuria in patients presenting with suspected acute renal colic and/or confirmed urolithiasis at the emergency department. Methods: A comprehensive literature search was conducted to find relevant data on prevalence of microhematuria in patients with suspected acute renal colic and/or confirmed urolithiasis. Data from each study regarding study design, patient characteristics and prevalence of microhematuria were retrieved. A random effect-model was used for the pooled analyses. Results: Forty-nine articles including 15′860 patients were selected through the literature search. The pooled microhematuria prevalence was 77% (95%CI: 73–80%) and 84% (95%CI: 80–87%) for suspected acute renal colic and confirmed urolithiasis, respectively. This proportion was much higher when the dipstick was used as diagnostic test (80 and 90% for acute renal colic and urolithiasis, respectively) compared to the microscopic urinalysis (74 and 78% for acute renal colic and urolithiasis, respectively). Conclusions: This meta-analysis revealed a high prevalence of microhematuria in patients with acute renal colic (77%), including those with confirmed urolithiasis (84%). Intending this prevalence as sensitivity, we reached moderate values, which make microhematuria alone a poor diagnostic test for acute renal colic or urolithiasis. Microhematuria could possibly still important to assess the risk in patients with renal colic.
    [Show full text]
  • Doenças Infeciosas Do Rim – Revisão Pictórica
    ACTA RADIOLÓGICA PORTUGUESA Maio-Agosto 2014 nº 102 Volume XXVI 37-43 Artigo de Revisão / Review Article DOENÇAS INFECIOSAS DO RIM – REVISÃO PICTÓRICA INFECTIOUS DISEASES OF THE KIDNEY – A PICTORIAL REVIEW Ângela Figueiredo1, Luísa Andrade2, Hugo Correia1, Nuno Ribeiro1, Rui Branco1, Duarte Silva1 1 - Serviço de Radiologia do Centro Hospitalar Resumo Abstract Tondela - Viseu Diretor: Dr. Duarte Silva A pielonefrite aguda é o tipo de infeção renal Acute pyelonephritis is the most common 2 - Serviço de Imagem Médica do Centro mais frequente, no entanto, o rim pode ser renal infection but a variety of other Hospitalar e Universitário de Coimbra afetado por vários outros processos infectious processes can be seen in the kidney. Diretor: Prof. Doutor Filipe Caseiro Alves infeciosos. Embora a avaliação imagiológica Although radiologic evaluation is not não seja necessária nos casos de pielonefrite necessary in cases of uncomplicated não complicada, pode desempenhar um papel pyelonephritis, it plays an important role in Correspondência importante nos doentes de risco, nos que não high-risk patients and in those who do not respondem de modo adequado à terapêutica respond to therapy or whose clinical Ângela Figueiredo e naqueles com uma apresentação clínica presentation is atypical. Serviço de Radiologia atípica. Although ultrasonography (US) is relatively Centro Hospitalar Tondela-Viseu A ecografia, embora pouco sensível nas fases insensitive in early stages of acute Av. Rei D. Duarte iniciais da pielonefrite, é o exame de primeira pyelonephritis, it is considered the first level 3504-509 Viseu linha por ser uma técnica acessível e não investigation technique for its availability and e-mail: [email protected] utilizar radiação ionizante.
    [Show full text]
  • Urinary System Diseases and Disorders
    URINARY SYSTEM DISEASES AND DISORDERS BERRYHILL & CASHION HS1 2017-2018 - CYSTITIS INFLAMMATION OF THE BLADDER CAUSE=PATHOGENS ENTERING THE URINARY MEATUS CYSTITIS • MORE COMMON IN FEMALES DUE TO SHORT URETHRA • SYMPTOMS=FREQUENT URINATION, HEMATURIA, LOWER BACK PAIN, BLADDER SPASM, FEVER • TREATMENT=ANTIBIOTICS, INCREASE FLUID INTAKE GLOMERULONEPHRITIS • AKA NEPHRITIS • INFLAMMATION OF THE GLOMERULUS • CAN BE ACUTE OR CHRONIC ACUTE GLOMERULONEPHRITIS • USUALLY FOLLOWS A STREPTOCOCCAL INFECTION LIKE STREP THROAT, SCARLET FEVER, RHEUMATIC FEVER • SYMPTOMS=CHILLS, FEVER, FATIGUE, EDEMA, OLIGURIA, HEMATURIA, ALBUMINURIA ACUTE GLOMERULONEPHRITIS • TREATMENT=REST, SALT RESTRICTION, MAINTAIN FLUID & ELECTROLYTE BALANCE, ANTIPYRETICS, DIURETICS, ANTIBIOTICS • WITH TREATMENT, KIDNEY FUNCTION IS USUALLY RESTORED, & PROGNOSIS IS GOOD CHRONIC GLOMERULONEPHRITIS • REPEATED CASES OF ACUTE NEPHRITIS CAN CAUSE CHRONIC NEPHRITIS • PROGRESSIVE, CAUSES SCARRING & SCLEROSING OF GLOMERULI • EARLY SYMPTOMS=HEMATURIA, ALBUMINURIA, HTN • WITH DISEASE PROGRESSION MORE GLOMERULI ARE DESTROYED CHRONIC GLOMERULONEPHRITIS • LATER SYMPTOMS=EDEMA, FATIGUE, ANEMIA, HTN, ANOREXIA, WEIGHT LOSS, CHF, PYURIA, RENAL FAILURE, DEATH • TREATMENT=LOW NA DIET, ANTIHYPERTENSIVE MEDS, MAINTAIN FLUIDS & ELECTROLYTES, HEMODIALYSIS, KIDNEY TRANSPLANT WHEN BOTH KIDNEYS ARE SEVERELY DAMAGED PYELONEPHRITIS • INFLAMMATION OF THE KIDNEY & RENAL PELVIS • CAUSE=PYOGENIC (PUS-FORMING) BACTERIA • SYMPTOMS=CHILLS, FEVER, BACK PAIN, FATIGUE, DYSURIA, HEMATURIA, PYURIA • TREATMENT=ANTIBIOTICS,
    [Show full text]
  • Role of Urinalysis in the Diagnosis of Chronic Kidney Disease (CKD)
    Research and Reviews Role of Urinalysis in the Diagnosis of Chronic Kidney Disease (CKD) JMAJ 54(1): 27–30, 2011 Kunitoshi ISEKI*1 Abstract As of the end of Year 2008, 1 out of 450 people was a dialysis patient in Japan, and patients with chronic kidney disease (CKD) at stages 3 and 4 accounted for nearly 10% of the total population. An epidemiological study in Okinawa that used the introduction of dialysis treatment as the outcome revealed that the 10-year cumulative incident rate of end-stage renal disease (ESRD) was about 3% of the participants who were positive (Ն 1ϩ) for both proteinuria and hematuria, while there was hardly any difference between those who were positive for hematuria alone and those who were negative for both proteinuria and hematuria. When the incidence of ESRD (dialysis introduction) was examined in relation to the severity of proteinuria (5 grades ranging from [Ϫ] to [Ն 3ϩ]) as determined by dipstick, the cumulative incidence rate during the 17-year observation period was 16% for proteinuria (Ն 3ϩ) and about 7% for proteinuria (2ϩ). In contrast, among participants who were negative for proteinuria, the rate of dialysis introduction in 10 years is about 1 out of 1 million. The CKD Practice Guide of the Japanese Society of Nephrology recommends referral to a nephrologist when a case meets any of the following 3 criteria: 1) 0.5g/g creatinine or higher, or proteinuria (Ն 2ϩ), 2) an estimated glomerular filtration rate of less than 50ml/min/1.73m2, or 3) positive results (Ն 1ϩ) for both proteinuria and hematuria tests.
    [Show full text]
  • EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ Adrian P.M
    European Urology European Urology 48 (2005) 363–371 EAU Guidelines EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ Adrian P.M. van der Meijdena,*, Richard Sylvesterb, Willem Oosterlinckc, Eduardo Solsonad, Andreas Boehlee, Bernard Lobelf, Erkki Rintalag for the EAU Working Party on Non Muscle Invasive Bladder Cancer aDepartment of Urology, Jeroen Bosch Hospital, Nieuwstraat 34, 5211 NL ’s-Hertogenbosch, The Netherlands bEORTC Data Center, Brussels, Belgium cDepartment of Urology, University Hospital Ghent, Ghent, Belgium dDepartment of Urology, Instituto Valenciano de Oncologia, Valencia, Spain eDepartment of Urology, Helios Agnes Karll Hospital, Bad Schwartau, Germany fDepartment of Urology, Hopital Ponchaillou, Rennes, France gDepartment of Urology, Helsinki University Hospital, Helsinki, Finland Accepted 13 May 2005 Available online 13 June 2005 Abstract Objectives: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy and follow-up of patients with urothelial carcinoma in situ (CIS) have been established. Method: The recommendations in these guidelines are based on a recent comprehensive overview and meta-analysis in which two panel members have been involved (RS and AVDM). A systematic literature search was conducted using Medline, the US Physicians’ Data Query (PDQ), the Cochrane Central Register of Controlled Trials, and reference lists in trial publications and review articles. Results: Recommendations are provided for the diagnosis, conservative and radical surgical treatment, and follow- up of patients with CIS. Levels of evidence are influenced by the lack of large randomized trials in the treatment of CIS. # 2005 Elsevier B.V. All rights reserved. Keywords: Bladder cancer; Carcinoma in situ; Bacillus Calmette-Guerin; Chemotherapy; Diagnosis; Treatment; Follow up 1.
    [Show full text]
  • Hematuria in the Child
    Hematuria and Proteinuria in the Pediatric Patient Laurie Fouser, MD Pediatric Nephrology Swedish Pediatric Specialty Care Hematuria in the Child • Definition • ³ 1+ on dipstick on three urines over three weeks • 5 RBCs/hpf on three fresh urines over three weeks • Prevalence • 4-6% for microscopic hematuria on a single specimen in school age children • 0.3-0.5% on repeated specimens Sources of Hematuria • Glomerular or “Upper Tract” – Dysmorphic RBCs and RBC casts – Tea or cola colored urine – Proteinuria, WBC casts, renal tubular cells • Non-Glomerular or “Lower Tract” – RBCs have normal morphology – Clots/ Bright red or pink urine The Glomerular Capillary Wall The Glomerular Capillary Wall Glomerular Causes of Hematuria • Benign or self-limiting – Benign Familial Hematuria – Exercise-Induced Hematuria – Fever-Induced Hematuria Glomerular Causes of Hematuria • Acute Glomerular Disease – Poststreptococcal/ Postinfectious – Henoch-Schönlein Purpura – Sickle Cell Disease – Hemolytic Uremic Syndrome Glomerular Causes of Hematuria • Chronic Glomerular Disease – IgA Nephropathy – Henoch-Schönlein Purpura or other Vasculitis – Alport Syndrome – SLE or other Collagen Vascular Disease – Proliferative Glomerulonephritis Non-Glomerular Hematuria • Extra-Renal • UTI • Benign urethralgia +/- meatal stenosis • Calculus • Vesicoureteral Reflux, Hydronephrosis • Foreign body • Rhabdomyosarcoma • AV M • Coagulation disorder Non-Glomerular Hematuria • Intra-Renal • Hypercalciuria • Polycystic Kidney Disease • Reflux Nephropathy with Renal Dysplasia •
    [Show full text]
  • Development and Validation of a Model to Predict Severe Hospital-Acquired Acute Kidney Injury in Non-Critically Ill Patients
    Journal of Clinical Medicine Article Development and Validation of a Model to Predict Severe Hospital-Acquired Acute Kidney Injury in Non-Critically Ill Patients Jacqueline Del Carpio 1,2,3,*, Maria Paz Marco 1,3, Maria Luisa Martin 1,3, Natalia Ramos 4 , Judith de la Torre 4,5, Joana Prat 6,7, Maria J. Torres 6,8, Bruno Montoro 9, Mercedes Ibarz 3,10 , Silvia Pico 3,10, Gloria Falcon 11, Marina Canales 11, Elisard Huertas 12, Iñaki Romero 13, Nacho Nieto 6,8, Ricard Gavaldà 14 and Alfons Segarra 1,4,† 1 Department of Nephrology, Arnau de Vilanova University Hospital, 25198 Lleida, Spain; [email protected] (M.P.M.); [email protected] (M.L.M.); [email protected] (A.S.) 2 Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain 3 Institute of Biomedical Research (IRBLleida), 25198 Lleida, Spain; [email protected] (M.I.); [email protected] (S.P.) 4 Department of Nephrology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; [email protected] (N.R.); [email protected] (J.d.l.T.) 5 Department of Nephrology, Althaia Foundation, 08243 Manresa, Spain 6 Department of Informatics, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; [email protected] (J.P.); [email protected] (M.J.T.); [email protected] (N.N.) 7 Department of Development, Parc Salut Hospital, 08019 Barcelona, Spain 8 Department of Information, Southern Metropolitan Territorial Management, 08028 Barcelona, Spain 9 Department of Hospital Pharmacy, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; [email protected] Citation: Carpio, J.D.; Marco, M.P.; 10 Laboratory Department, Arnau de Vilanova University Hospital, 25198 Lleida, Spain Martin, M.L.; Ramos, N.; de la Torre, 11 Technical Secretary and Territorial Management of Lleida-Pirineus, 25198 Lleida, Spain; J.; Prat, J.; Torres, M.J.; Montoro, B.; [email protected] (G.F.); [email protected] (M.C.) 12 Ibarz, M.; Pico, S.; et al.
    [Show full text]